IP Library Granted Patent US 8,845,612
Granted Patent B2
US 8,845,612 · App. 12/853,922 · Granted Sep 30, 2014

Methods for iontophoretically treating nausea and migraine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,845,612
App. No.
12/853,922
Granted
Sep 30, 2014
Kind
B2
Abstract

Methods for treating nausea and migraine by iontophoretically administering triptan compounds are provided.

Claims (20)

1. A method for treating nausea in a subject suffering from a migraine, the method comprising: iontophoretically administering an effective amount of a triptan compound to a subject suffering from a migraine, such that the nausea is treated without cardiovascular side effects, wherein the triptan compound is administered iontophoretically in a two phase manner, comprising:

a first phase, wherein the triptan compound is administered with a current of about 4 mA for about an hour; and

a second phase, wherein the triptan compound is administered with a current of about 2 mA for about three hours.

2. The method of claim 1 , wherein the current does not substantially irritate the subject's skin.

3. The method of claim 1 or claim 2 , wherein the current does not result in a skin erythema score of greater than 2.5, of greater than 2.0, of greater than 1.5, or of greater than 1.0, immediately after patch removal.

4. The method of claim 1 , wherein the subject is a human.

5. The method of claim 1 , wherein the subject is suffering from a prodromal migraine symptom, and wherein the prodromal migraine symptom is treated.

6. The method of claim 1 , wherein the subject is suffering from a migraine aura, and wherein the migraine aura is treated.

7. The method of claim 1 , wherein the nausea is reduced in the subject by at least about 50%.

8. The method of claim 1 , wherein the nausea is treated without migraine-associated absorption reduction.

9. The method of claim 1 , wherein the migraine is aborted in the subject.

10. The method of claim 1 , wherein the nausea is treated without triptan side effects.

11. The method of claim 1 , wherein the nausea is treated for at least two hours.

12. The method of claim 1 , wherein the migraine is treated for at least two hours.

13. The method of claim 1 , wherein the subject is suffering from a migraine with a pain severity score of 2 or 3.

14. The method of claim 1 , wherein the subject is suffering from migraine induced nausea or vomiting.

15. The method of claim 1 , wherein the triptan compound is a sumatriptan or a pharmaceutically acceptable salt thereof.

16. The method of claim 15 , wherein the subject's headache score is reduced from a score of about 3 to about 2, to about 1, or to about 0.

17. The method of claim 15 , wherein the subject's headache score is reduced from a score of about 2 to about 1, or to about 0.

18. The method of claim 15 , wherein iontophoretically administering the triptan compound comprises a current which results in minimal or no erythema.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE INADVERTENTLY FILED ASSIGNMENT DOCUMENT AND REMOVE IT COMPLETELY FROM US6745071 PREVIOUSLY RECORDED ON REEL 035278 FRAME 0202. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNOR'S INTEREST. Recorded Oct 23, 2015
From: NUPATHE INC.
To: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Reel/Frame 036933/0165 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2015
From: NUPATHE INC.
To: TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Reel/Frame 035278/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2012
From: PIERCE, MARK; O'NEILL, CAROL; SEBREE, TERRI B.
To: NUPATHE, INC.
Reel/Frame 027673/0576 →